Press release
Hereditary Angioedema - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Astria Therapeutics Inc, Attune Pharmaceuticals, BioMarin Pharmaceutical
Hereditary Angioedema
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.globalinsightservices.com/request-sample/GIS31264
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called C1 inhibitor.
Symptoms are severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing, and difficulty breathing.
Hereditary Angioedema is diagnosed by blood tests that detect decreased levels of complement proteins and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.
Hereditary Angioedema is treated by medications, such as corticosteroids, antihistamines and epinephrine.
Read more about Hereditary Angioedema Insight here: https://www.globalinsightservices.com/reports/hereditary-angioedema-drug-pipeline-landscape/
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Hereditary Angioedema treatment such as CSL312, Sebetralstat, BMN 331, PHVS719, and others. Key players involved in the development of therapies to treat Hereditary Angioedema are CSL Behring, Kalvista Pharmaceuticals and others. Four drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
In Nov 2022, Ionis Pharmaceuticals Inc presented positive Phase II study of open label extension results of donidalosen. In Oct 2022, KalVista Pharmaceuticals announced positive Phase I data of sebetralstat. In August 2022, Global Biotechnology announed positive top-line Phase III results for garadacimab.
For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31264
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Angioedema - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Astria Therapeutics Inc, Attune Pharmaceuticals, BioMarin Pharmaceutical here
News-ID: 2943961 • Views: …
More Releases from Global Insight Services
Governance Risk and Compliance (GRC) Platform Market to Expand From $53.5 Billio …
The Governance Risk And Compliance (GRC) Platform Market has emerged as a cornerstone for organizations striving to enhance accountability, streamline risk management, and meet growing regulatory demands. GRC platforms provide an integrated framework that enables companies to monitor compliance, manage risks, and ensure governance practices are aligned with industry standards. By combining risk assessment, audit management, compliance tracking, and policy enforcement, these platforms empower businesses to strengthen decision-making and safeguard…
Electronic Manufacturing Services (EMS) Market to Expand From $504.22 Billion in …
The Electronic Manufacturing Services (EMS) Market has become one of the most crucial sectors in the global technology-driven economy. EMS refers to the outsourcing of design, production, testing, and distribution of electronic components for original equipment manufacturers (OEMs). These services are indispensable across industries such as consumer electronics, automotive, telecommunications, and healthcare. In 2024, the EMS sector continues to play a pivotal role in improving efficiency, lowering production costs, and…
Catamaran Market Is Anticipated To Expand From $4.2 Billion In 2024 To $7.8 Bill …
Market Overview
The Catamaran Market is witnessing remarkable expansion, driven by the growing demand for recreational boating, marine tourism, and eco-friendly vessel options. Catamarans, recognized for their stability, spaciousness, and fuel efficiency, are increasingly preferred for leisure sailing, luxury tourism, and competitive racing. The market includes a wide range of offerings such as sailing catamarans, power catamarans, luxury yachts, and charter vessels, each catering to unique consumer preferences.
Innovations in sustainable…
Gear Motor Market to Expand From $24.5 Billion in 2024 to $39.8 Billion by 2034 …
The gear motor market is witnessing steady growth as industries worldwide increasingly depend on reliable and energy-efficient motion control systems. Gear motors, which combine a motor with a gearbox, play a vital role in converting electrical energy into mechanical torque with higher efficiency. These systems are essential across sectors like automotive, robotics, manufacturing, and renewable energy, offering enhanced precision, power transmission, and performance. The market is strongly supported by the…
More Releases for Hereditary
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
